Moderna’s Omicron-containing bivalent booster candidate, mRNA-1273.214, demonstrated higher neutralizing antibody response
On Jul. 11, 2022, Moderna announced new clinical data on its bivalent Omicron (BA.1) booster candidate, mRNA-1273.214. One…
NIH launched clinical trial of mRNA Nipah virus vaccine
On Jul. 11, 2022, the National Institute of Allergy and Infectious Diseases (NIAID) launched an early-stage clinical trial…
Trial of potential universal flu vaccine opened at NIH Clinical Center
On Jun. 28, 2022, the National Institutes of Health (NIH) announced that a Phase 1 clinical trial of…
Novavax COVID-19 vaccine Nuvaxovid recommended for expanded conditional marketing authorization in EU for adolescents aged 12 through 17
On Jun. 23 2022, Novavax announced that the Nuvaxovid (NVX-CoV2373) COVID-19 vaccine had been recommended for expanded conditional…
Novavax COVID-19 vaccine Nuvaxovid provisionally registered in Australia as booster in individuals aged 18 and over
On Jun. 13 2022, Novavax announced that the Australian Therapeutic Goods Administration (TGA) had granted provisional registration of…
Moderna announced Omicron-containing bivalent booster candidate mRNA-1273.214 demonstrated superior antibody response against Omicron
On Jun. 8, 2022, Moderna announced new clinical data on its Omicron-containing bivalent COVID booster candidate, mRNA-1273.214, containing…
Veru submitted EUA to U.S. FDA for Sabizabulin, its anti-Inflammatory drug candidate for hospitalized COVID-19 patients
On Jun. 7, 2022, Veru announced that is had submitted an emergency use authorization (EUA) application to the…
Immune modulator drugs improved survival for people hospitalized with COVID-19
On Jun. 2, 2022, the U.S. National Institutes of Health announced that a large randomized, placebo-controlled clinical trial…
IAVI and Moderna launched first-in-Africa clinical trial of mRNA HIV vaccine development program
On May 18, 2022, Moderna and the nonprofit scientific research organization IAVI announced that the first participant screenings…
NIH launched clinical trial of Epstein-Barr virus vaccine
On May 6, 2022, the National Institute of Allergy and Infectious Diseases (NIAID) announced that it had launched…
Biotechnology | COVID-19 | FDA | Life Science News | Vaccine
Pfizer and BioNTech submitted application for U.S. EUA for COVID-19 vaccine booster dose in children 5 through 11 years of age
On Apr. 26, 2022, Pfizer and BioNTech submitted an application to the U.S. Food and Drug Administration (FDA)…
Novavax announced initiation of COVID-19 vaccine booster study in adolescents in phase 3 PREVENT-19 trial
On Apr. 22, 2022, Novavax announced initial results from the Phase 1/2 clinical trial of its COVID-Influenza Combination…
Initial results from Novavax’ COVID-19-Influenza vaccine trial were first to show feasibility of combination vaccine
On Apr. 20, 2022, Novavax announced initial results from the Phase 1/2 clinical trial of its COVID-Influenza Combination…
Tonix Pharm announced results of retrospective observational database study in over 50,000 long COVID patients
On Apr. 20, 2022, Tonix Pharmaceuticals announced the results of a retrospective observational database study in over 50,000…
Pfizer and BioNTech data demonstrated high immune response following booster dose of COVID-19 vaccine in children 5 through 11 years of age
On Mar. 14, 2022, Pfizer and BioNTech announced positive results from a Phase 2/3 clinical trial evaluating the…
Merck announced FDA granted breakthrough therapy designation for V116, investigational 21-valent pneumococcal conjugate vaccine, for prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults
On Apr. 14, 2022, Merck announced that V116, the companyï¾’s investigational 21-valent pneumococcal conjugate vaccine, had received Breakthrough…
Swissmedic granted conditional Marketing Authorization for Novavax COVID-19 vaccine
On Apr. 13, 2022, Novavax announced that Swissmedic had granted Novavax conditional marketing authorization (CMA) for Nuvaxovid COVID-19…
Veruï¾’s novel COVID-19 drug candidate reduced deaths by 55% in hospitalized patients in interim analysis of phase 3 study
On Apr. 11, 2022, Veru announced positive efficacy and safety results from a planned interim analysis of the…
NIH began clinical trial evaluating second COVID-19 booster shots in adults
On Mar. 31, 2022, the National Institutes of Health (NIH) and Moderna announced a phase 2 clinical trial…
Sorrento reported FDA clearance for phase 2/3 study for Abivertinib in treatment of pospitalized patients with severe pneumonia due to COVID-19
On Mar. 31, 2022, Sorrento Therapeutics announced that the FDA had given clearance to commence the Phase 3…
Lucira’s COVID-19 & flu at-home molecular test showed Positive clinical trial results
On Mar. 30, 2022, Lucira Health announced that preliminary clinical trial results for its candidate COVID-19 & Flu…
CureVac and GSK started clinical development of second-generation COVID-19 vaccine Candidate, CV2CoV
On Mar. 30, 2022, CureVac announced that the first participant was dosed in a Phase 1 study of…
Icosavax announced topline interim results from its ongoing Phase 1/2 clinical trial of IVX-411, a VLP vaccine candidate displaying the SARS-CoV-2 receptor-binding domain (RBD).
On Mar. 25, 2022, Icosavax announced the first subjects had been dosed with IVX-411, a virus-like particle (VLP)…
Moderna announced COVID-19 vaccine phase 2/3 study in children 6 months to Under 6 years met Its primary endpoint
On Mar. 23, 2022, Moderna announced positive interim data from the Phase 2/3 KidCOVE study of the Moderna…
NIH launched program to offer molecular characterization of childhood cancers
On Mar. 21, 2022, in support of the Cancer Moonshot? goal of fostering data sharing in cancer research,…
Researchers generated the first complete, gapless sequence of a human genome
On Mar. 21, 2022, in support of the Cancer Moonshot goal of fostering data sharing in cancer research,…
COVID-19 | HIV | Life Science News | NIH | Non-Profit Research | Vaccine
NIH launched clinical trial of three mRNA HIV vaccines
On Mar. 14, 2022, researchers from the National Institute of Allergy and Infectious Diseases (NIAID) announced they had…
Moderna announced first participant dosed in phase 2 study of Omicron-specific bivalent booster candidate
On Mar. 10, 2022, Moderna announced that the first participant had been dosed in the Phase 2 study…
Cocrystal Pharma initiated enrollment in phase 1 influenza a study with novel, broad-spectrum, orally administrated antiviral CC-42344
On Mar. 10, 2022, Cocrystal Pharma announced dosing of the first subjects in a Phase 1 clinical trial…
City of Hope COVID-19 vaccine showed effectiveness in phase 1 trial
On Mar. 10, 2022, the City of Hope announced that its COVID-19 investigational vaccine licensed to GeoVax Labs…